ArticleCell2017
On the Design of Combination Cancer Therapy.
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer.Cancer control : journal of the Moffitt Cancer CenterTrial
- Curcumin Bound Seleno-BSA, a Novel Bifunctional Macromolecular Therapeutic System Against A549 Lung Cancer Cells: Photophysical Characterizations, Cellular Uptake, and Efficacy.Chemistry, an Asian journal · 2026Article
- Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.EMBO molecular medicine · 2026Article
- Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma.Science advances · 2025Article
- Synergistic Anticancer Effects of Fermented Noni Extract Combined with 5-Fluorouracil, Doxorubicin, and Vincristine on A549, MCF-7, and SH-SY5Y Cell Models.Current issues in molecular biology · 2025Article
- Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models.Cell death & disease · 2025Article
- Adjuvant Anti-tumor Therapy with Polyphenolic Compounds: A Review.Current medicinal chemistry · 2025Review
- Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.Journal of nanobiotechnology · 2024Review
- A network-based trans-omics approach for predicting synergistic drug combinations.Communications medicine · 2024Article
- A landscape of response to drug combinations in non-small cell lung cancer.Nature communications · 2023Article
- A TMVP1-modified near-infrared nanoprobe: molecular imaging for tumor metastasis in sentinel lymph node and targeted enhanced photothermal therapy.Journal of nanobiotechnology · 2023Article
- Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells.Materials today. Bio · 2023Review
- Docking Design of the Different Microcapsules in Aqueous Solution and Its Quantitative On-Off Study.Polymers · 2023Article
- Article
- Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.Molecular cancer therapeutics · 2022Article
- 2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy.Bioactive materials · 2022Article
- Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD.Inflammatory bowel diseases · 2022Review
- Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.Bioscience reports · 2022Review
- Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells.Heliyon · 2022Article
- Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Combination therapy programs are the hallmark of the successful treatment of all forms of human malignancies. In this issue of Cell, Palmer and Sorger present data suggesting that cell culture results indicative of synergistic anticancer drug interactions rarely translate clinically and that the results of combination therapies in mouse models or human clinical trials, even if successful, are best explained by the independent activities of the individually administered drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.